. 2021 Oct 3;14:159. doi: 10.1186/s13045-021-01172-5

Table 1.

Symptoms, clinical signs, and in vivo confocal microscopy of the cornea in the worst eye of a patient treated with belantamab mafodotin

Time (weeks)	Pre-	3	6	9	12	15	36
Symptoms, vision, and slit-lamp examination of the cornea
Blurred vision (CTCAE, 0–4)	0	0	3*	0	1	1	0
Photophobia (CTCAE, 0–4)	0	1	2	0	0	0	0
Visual acuity	20/20	20/20	20/40*	20/20	20/25	20/25	20/20
SPK (0–5)	0	1	3*	2	2	2	0
Microcysts	None	None	Diffuse	Diffuse	Diffuse	Diffuse	None
In vivo confocal microscopy of the cornea. Location: peripheral/central
Epithelial microcysts
Density (/mm²)			25/6.3	6.3/12.5	0/6.3	62.5/62.5	0/0
Average size (μm)	0/0	0/0	10.7/14.3	18.4/14.7	0/14.7	18.8/15.7
Circularity (0–1)			0.67/0.9	0.88/0.94	/0.94	0.77/0.84
Hyperreflective deposits: superficial epithelium
Density (/μm²)		31.3^§/0	138/87.5	62.5/81.3	56.3/62.3	62.5/106
Average size (μm)	0/0	8.5/na	6.8/7.5	7.1/9.1	7.6/7.4	8.8/9	0/0
Circularity (0–1)		0.72/na	0.67/0.69	0.72/0.80	0.62/0.65	0.81/0.83
Hyperreflective deposits: basal epithelium
Density (/μm²)		68.8^§/0	381/219	343/119	131/93.8	93.8/206
Average size (μm)	0/0	9.0/na	9.9/8.9	6.9/9.1	8.6/7.2	8.7/9.2	0/0
Circularity (0–1)		0.56/na	0.61/0.64	0.75/0.75	0.63/0.59	0.67/0.74
Hyperreflective deposits: sub-Bowman nerve plexus layer (anterior stroma)
Density (/μm²)		100^§/0	225/169	62.5/50	37.5/68.8	75/31.3
Average size (μm)	0/0	6.4/na	8.2/8.9	8/6.3	7.5/6.4	6.6/7.9	0/0
Circularity (0–1)		0.66/na	0.61/0.64	0.48/0.64	0.64/0.72	0.69/0.59
Treatment (belantamab mafodotin)
Delivered dose after exams (mg/kg)	2.5	2.5	0	1.9	1.9	0	0
Cumulative dose (mg)	0	180	360	360	490	620	620

CTCAE common terminology criteria for adverse events, na not applicable, SPK superficial punctuate keratitis. (Oxford’s score)

^*Clinical ocular features that influenced the dose adjustment/temporary discontinuation of belantamab mafodotin

^§IVCM putative preclinical markers for ocular toxicity (before any clinical signs/symptoms)